Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.61 |
| ▸ | ADH1C | P00326 | 1/20 | 0.61 |
| ▸ | ADH1A | P07327 | 1/20 | 0.61 |
| ▸ | ADH7 | P40394 | 1/20 | 0.61 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8763196 | 0.88 | ADH1B (0.76) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL24677605 | 0.83 | ADH1B (0.57) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL17503962 | 0.82 | ADH1B (0.61) | ADH1BADH1CADH1AADH7ANPEP | |
| SCHEMBL8763263 | 0.81 | ADH1B (0.67) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL23266841 | 0.78 | GFER (0.52) | ADH1BADH1CADH1AADH7GFER | |
| SCHEMBL2125786 | 0.78 | TDP1 (0.55) | ANPEPERAP2GFERALDH1A1CYP3A4 | |
| SCHEMBL5221625 | 0.77 | ADH1B (0.61) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL1486309 | 0.77 | ADH1B (0.61) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL4633463 | 0.77 | ADH1B (0.61) | ADH1BADH1CADH1AADH7ALDH1A1 | |
| SCHEMBL513192 | 0.77 | ADH1B (0.61) | ADH1BADH1CADH1AADH7CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1038 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118159298-A | Method for producing antibody-linker conjugates | 阿拉里斯生物技术股份公司 | 2024-06-07 | — | — | CN | claimed |
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-06-04 | — | — | US | claimed |
| CN-117980327-A | Specific coupling of antibodies | 杭州多禧生物科技有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2024047172-A1 | AN INTEGRIN ALPHA10 ANTIBODY DRUG CONJUGATE | TARGINTA AB (SE) | 2024-03-07 | — | — | WO | claimed |
| WO-2024017219-A1 | TUMOR MICROENVIRONMENT-ACTIVATED CYTOKINE AND USE THEREOF | 亚飞（上海）生物医药科技有限公司 | 2024-01-25 | — | — | WO | claimed |
| CN-117417429-A | Tumor microenvironment activated cytokine and application thereof | 亚飞（上海）生物医药科技有限公司 | 2024-01-19 | — | — | CN | claimed |
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-01-16 | — | — | US | claimed |
| US-11866496-B2 | Humanized anti-CD79B antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2024-01-09 | — | — | US | claimed |
| CN-110143999-B | Cytotoxic and antimitotic compounds and methods of use thereof | 酵活英属哥伦比亚省公司 | 2023-12-05 | — | — | CN | claimed |
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2023-11-23 | — | — | US | claimed |
| WO-2007140371-A2 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2007-12-06 | — | — | WO | claimed |
| EP-1791565-A2 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | Genentech, Inc. (US) | 2007-06-06 | — | — | EP | claimed |
| EP-1786838-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2007-05-23 | — | — | EP | claimed |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2007-04-26 | — | — | US | claimed |
| WO-2006034488-A2 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | GENENTECH, INC. (US) | 2006-03-30 | — | — | WO | claimed |
| WO-2006029183-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2006-03-16 | — | — | WO | claimed |
| US-20050272118-A1 | Novel composition and methods for the treatment of immune related diseases | GENENTECH, INC. | 2005-12-08 | — | — | US | claimed |
| US-20050106644-A1 | Compositions and methods for the diagnosis and treatment of tumor | GENENTECH, INC. | 2005-05-19 | — | — | US | claimed |
| US-20050107595-A1 | Compositions and methods for the diagnosis and treatment of tumor | GENENTECH, INC. | 2005-05-19 | — | — | US | claimed |
| EP-0624377-A2 | Lysosomal enzyme-cleavable antitumor drug conjugates | Bristol-Myers Squibb Company (US) | 1994-11-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | SP1, GLUL, TGM2 | ADH1B 3185/4885ADH1C 3858/4885ADH1A 3537/4885 |
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | ADH1B 4478/4885ADH1C 3680/4885ADH1A 4061/4885 |
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | TEKT1, TEK, CD2BP2 | ADH1B 4813/4885ADH1C 4127/4885ADH1A 4568/4885 |
| US-11866496-B2 | Humanized anti-CD79B antibodies and immunoconjugates and methods of use | CD99, CD79B, CD47 | ADH1B 3249/4885ADH1C 3542/4885ADH1A 4039/4885 |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | LNPEP, CSTB, ALB | ADH1B 3040/4885ADH1C 2188/4885ADH1A 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.